Microvision, Inc. (NASDAQ:MVIS) stock popped after the display screen developer announced its collaboration with an unnamed global consumer electronics brand. Microvision, Inc. (NASDAQ:MVIS) weekly performance is 1.52%. On last trading day company shares ended up $2.01. Analysts mean target price for the company is $3.50. Microvision, Inc. (NASDAQ:MVIS) distance from 50-day simple moving average (SMA50) is 14.99%.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) rose almost in extended trading on news that the company will resume clinical trials for its experimental drug PEGPH20, which is currently being tested for its efficacy as a first-line therapy drug to treat pancreatic cancer. Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares advanced 12.00% in last trading session and ended the day on $9.05. HALO Gross Margin is 80.00% and its return on assets is -70.20%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) quarterly performance is -36.36%.
Amazon.com, Inc. (NASDAQ:AMZN) has sent out invitations to a HW launch event on June 18. Macquarie believes Amazon will finally launch the long-rumored Amazon phone and believe speculation about a 3D motion-responsive interface is likely right. The analyst said the phone will have a “forked version of the Android” and will drive more users into the Amazon ecosystem. Shares are Outperform rated with a $430 price target. Amazon.com, Inc. (NASDAQ:AMZN) shares moved up 5.47% in last trading session and was closed at $323.57, while trading in range of $306.90 – $327.94. Amazon.com, Inc. (NASDAQ:AMZN) year to date (YTD) performance is -18.86%.
O n 2 JUNE FireEye Inc (NASDAQ:FEYE) announced that from the June 12, 2014, they will provide IPS (intrusion prevention system) along with FireEye Inc (NASDAQ:FEYE)’s Network Threat Prevention Platform. FireEye Inc (NASDAQ:FEYE) ended the last trading day at $32.68. Company weekly volatility is calculated as 5.96% and price to cash ratio as 8.11. FireEye Inc (NASDAQ:FEYE) showed a negative weekly performance of -5.69%.
On 2 JUNE Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the company has entered into a collaboration agreement with Oncothyreon Inc. Both the above mentioned companies will collaborate on the combined clinical trial of Varlilumab (CDX-1127) and ONT-10. This Phase lb trial will be an open label study where the ONT-10 will be observed as the recommended single agent dose combined with varlilumab at 2 dose level for patients suffering with ovarian or breast cancer. Celldex Therapeutics, Inc. (NASDAQ:CLDX) net profit margin is -94.10% and weekly performance is -5.69%. On last trading day company shares ended up $15.15. Analysts mean target price for the company is $47.20. Celldex Therapeutics, Inc. (NASDAQ:CLDX) distance from 50-day simple moving average (SMA50) is -22.34%.
Leave a Reply